GERD vs Peptic Ulcer Disease: How to Tell Them Apart
Both GERD and peptic ulcer disease are acid-related upper GI disorders that respond to acid suppression and are worked up with upper endoscopy. The core axis that separates them is the site and mechanism of injury: GERD is failure of the lower esophageal sphincter (LES) barrier allowing acid into the esophagus, while peptic ulcer disease is mucosal ulceration of the stomach or duodenum, most often driven by H. pylori or NSAID/aspirin use. Their long-term cancer risks also differ in site and driver — reflux predisposes to esophageal adenocarcinoma via Barrett's, whereas H. pylori-associated (not NSAID-induced) gastric disease predisposes to gastric adenocarcinoma.
How to tell them apart
| Feature | GERD (Gastroesophageal Reflux Disease) | Peptic Ulcer Disease |
|---|---|---|
| Site of pathology | Esophagus and gastroesophageal junction — acid refluxing above a failed LES | Ulceration of the stomach (classically the lesser curvature) or duodenum; ulcers in the jejunum suggest a gastrin-driven process |
| Underlying mechanism | Failure of the LES antireflux barrier — transient LES relaxations, a hypotensive LES, hiatal hernia, impaired esophageal clearance, or delayed gastric emptying | Mucosal breakdown from H. pylori infection or NSAID/aspirin use; in gastrin-secreting states (Zollinger-Ellison), acid hypersecretion causes recurrent ulcers |
| Typical symptoms | Heartburn (retrosternal burning worse after meals and with recumbency) and effortless regurgitation; dysphagia signals a complication such as stricture | Epigastric pain classically related to meals (duodenal ulcers often relieved by food, gastric ulcers worsened by food), but can be clinically silent — occult GI blood loss producing iron deficiency anemia may be the only clue |
| Role of H. pylori | Not a causal driver; H. pylori may even protect against esophageal adenocarcinoma, possibly by reducing acid output in corpus-predominant infection | H. pylori is a central cause; eradication prevents recurrence and lowers long-term complication and cancer risk, and eradication must be confirmed |
| Cancer risk / surveillance | Chronic reflux drives Barrett's esophagus (salmon-colored columnar mucosa with goblet cells) and esophageal adenocarcinoma; non-dysplastic Barrett's carries roughly 0.1–0.3% per year risk with surveillance EGD every 3–5 years | H. pylori-associated gastric disease raises gastric adenocarcinoma risk through the metaplasia–dysplasia sequence; a gastric ulcer must be biopsied to exclude malignancy. NSAID-induced ulcers without H. pylori do not carry this cancer risk |
| Characteristic complications | Peptic stricture, Barrett's metaplasia, and extraesophageal disease (chronic cough, laryngitis, asthma, dental erosions) | Gastrointestinal bleeding with occult blood loss and iron deficiency anemia, and perforation |
| Treatment focus | Lifestyle modification, PPIs dosed before meals, and fundoplication for refractory or complicated disease | PPI therapy to heal the ulcer, plus H. pylori eradication (14-day triple or quadruple therapy) with confirmation of eradication to prevent recurrence; stop offending NSAIDs/aspirin. Repeat EGD in 6–8 weeks is indicated for gastric ulcers to confirm healing and exclude malignancy, whereas uncomplicated duodenal ulcers do not require follow-up endoscopy |
The reasoning
Anchor on symptom pattern and site. Retrosternal burning worse after meals and lying down, plus regurgitation, points to reflux into the esophagus (GERD), and endoscopy or pH-impedance testing confirms acid exposure and screens for Barrett's. When the picture is epigastric ulcer pain, occult bleeding, or iron deficiency anemia — especially with NSAID/aspirin use or H. pylori — think peptic ulcer disease and pursue EGD with biopsy plus H. pylori testing. Remember that PPI therapy heals most ulcers, but H. pylori eradication (with confirmation) is the pivot for preventing recurrence and complications, while GERD hinges on restoring the antireflux barrier and controlling acid. A gastric ulcer always needs biopsy to exclude malignancy and follow-up EGD to confirm healing, whereas an uncomplicated duodenal ulcer does not. Cancer risk also arbitrates by site and driver: reflux disease trends toward esophageal adenocarcinoma via Barrett's, while H. pylori-associated (not NSAID-induced) ulcer disease trends toward gastric adenocarcinoma.
Key tests
- Upper endoscopy (EGD): in GERD reveals esophagitis, stricture, or Barrett's (salmon-colored mucosa with goblet cells); in PUD reveals gastric or duodenal ulcers, with biopsy of gastric ulcers to exclude malignancy and to test for H. pylori
- Urea breath test: detects active H. pylori infection in PUD (labeled urea split by bacterial urease releases labeled CO2); withhold PPIs ~2 weeks and wait 4+ weeks after antibiotics to avoid false negatives — not a test for GERD
- pH-impedance monitoring: objectively confirms acid reflux and clarifies PPI-refractory GERD; not part of the PUD workup
- Stool guaiac and iron studies: guaiac-positive stool with microcytic, low-ferritin iron deficiency anemia points to occult GI blood loss from an ulcer (or malignancy)
What they share
- Both are acid-related upper GI disorders that improve with proton pump inhibitor (PPI) therapy
- Both are evaluated with upper endoscopy (EGD), often with mucosal biopsy
- Both can be provoked or worsened by lifestyle and dietary factors
- Both can present with epigastric or upper abdominal discomfort, creating overlap in vague dyspeptic presentations
Pitfalls
- Do not simply escalate PPI dose in "PPI-refractory GERD" — first verify compliance and pre-meal timing and confirm the diagnosis; consider eosinophilic esophagitis, functional heartburn, rumination, achalasia, or bile reflux
- Assuming a gastric ulcer is benign — it must be biopsied to exclude malignancy, and healing should be confirmed on repeat EGD; uncomplicated duodenal ulcers, by contrast, do not require follow-up endoscopy
- Missing peptic ulcer disease in patients with no abdominal pain — occult GI blood loss and iron deficiency anemia may be the only presentation, and GI malignancy must also be excluded
- Failing to confirm H. pylori eradication — treatment fails in a substantial minority, and testing too early (or while on a PPI) produces false negatives, risking ulcer recurrence
- Forgetting that recurrent or jejunal ulcers with markedly elevated gastrin suggest a hypersecretory (Zollinger-Ellison) cause rather than routine GERD
Practice this the way the exam tests it — on branching cases where your decisions shape the patient.